The mineralocorticoid receptor in endothelial physiology and disease: Novel concepts in the understanding of erectile dysfunction

Current Pharmaceutical Design

Volumn 14, Issue 35, 2008, Pages 3749-3757

  Caprio, Massimiliano ^a,b   Mammi, Caterina ^a   Jaffe, Iris Z ^c   Zennaro, Maria Christina ^d,e,f   Aversa, Antonio ^g   Mendelsohn, Michael E ^c   Fabbri, Andrea ^b   Rosano, Giuseppe M C ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c TUFTS MEDICAL CENTER   (United States)

^d INSERM   (France)

^e l'alimentation et l'Environnement   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aldosterone; Endothelium; eNOS; Erectile dysfunction; Mineralocorticod receptor; RHO kinase; Vasoconstriction; Vasodilation

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALDOSTERONE; ANDROGEN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ENDOTHELIAL GROWTH FACTOR RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GROWTH FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE; RAC PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SPIRONOLACTONE; STEROID RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CONGESTIVE HEART FAILURE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPITHELIUM; ERECTILE DYSFUNCTION; GENETIC TRANSCRIPTION; GYNECOMASTIA; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; IMMUNITY; INFLAMMATION; LIGAND BINDING; NONHUMAN; ONCOGENE SRC; PENIS ERECTION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; DRUG ANTAGONISM; ENZYMOLOGY; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ERECTILE DYSFUNCTION; HUMANS; MALE; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, MINERALOCORTICOID; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 61449213235     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786898743     Document Type: Review

References (95)

1. Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 2007; 7: 151-7.
2. Pitt, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
4. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103: 425-31.
5. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765-70.
6. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643-50.
7. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102: 1359-67.
8. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185-94.
9. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.
10. Tait JF, Tait SA. A steroids memoir. A decade (or more) of electrocortin (aldosterone). Steroids 1988; 51: 213-50.
11. Bridgham JT, Carroll SM, Thornton JW. Evolution of hormone-receptor complexity by molecular exploitation. Science 2006; 312: 97-101.
12. Hu X, Funder JW. The evolution of mineralocorticoid receptors. Mol Endocrinol 2006; 20: 1471-8.
13. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-75.
14. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-86.
15. Stockand JD. New ideas about aldosterone signaling in epithelia. Am J Physiol Renal Physiol 2002; 282: F559-F576
16. Verrey F, Loffing J, Zecevic M, Heitzmann D, Staub O. SGK1: aldosterone-induced relay of Na+ transport regulation in distal kidney nephron cells. Cell Physiol Biochem 2003; 13: 21-8.
17. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-9.
18. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-5.
19. Funder JW. Mineralocorticoid receptors: Distribution and activation. Heart Fail Rev 2005; 10: 15-22.
20. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett 1999; 464: 9-13.
21. Meyer U, Kruhoffer M, Flugge G, Fuchs E. Cloning of glucocorticoid receptor and mineralocorticoid receptor cDNA and gene expression in the central nervous system of the tree shrew (Tupaia belangeri). Brain Res Mol Brain Res 1998; 55: 243-53.
22. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
23. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71: 503-10.
24. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 2007; 27: 799-805.
25. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005; 54: 1023-31.
26. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 2005; 26: 313-21.
27. Burton TJ, Cooper DM, Dunning-Davies B, Mansour D, Masada N, Ferguson DR. Aldosterone stimulates active Na+ transport in rabbit urinary bladder by both genomic and non-genomic processes. Eur J Pharmacol 2005; 510: 181-6.
28. Thomas W, McEneaney V, Harvey BJ. Aldosterone-induced signalling and cation transport in the distal nephron. Steroids 2008; 73: 979-84.
29. Alzamora R, Brown LR, Harvey BJ. Direct binding and activation of protein kinase C isoforms by aldosterone and 17beta-estradiol. Mol Endocrinol 2007; 21: 2637-50.
30. Krug AW, Schuster C, Gassner B, Freudinger R, Mildenberger S, Troppmair J, et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem 2002; 277: 45892-7.
31. Krug AW, Grossmann C, Schuster C, Freudinger R, Mildenberger S, Govindan MV, et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 2003; 278: 43060-6.
32. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45: 773-9.
33. Braun S, Losel R, Wehling M, Boldyreff B. Aldosterone rapidly activates Src kinase in M-1 cells involving the mineralocorticoid receptor and HSP84. FEBS Lett 2004; 570: 69-72.
34. Rossol-Haseroth K, Zhou Q, Braun S, Boldyreff B, Falkenstein E, Wehling M, et al. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem Biophys Res Commun 2004; 318: 281-8.
35. Thomas CM, Smart EJ. Caveolae structure and function. J Cell Mol Med 2008; 12: 796-809.
36. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci USA 2004; 101: 17126-31.
37. Feletou M, Vanhoutte PM. Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 291: H985-1002.
38. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
39. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. Intern Med J 2003; 33: 380-6.
40. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern Med J 2003; 33: 450-62.
41. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810
42. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004; 109: 2213-20.
43. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-36.
44. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
45. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-97
46. Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol 2003; 23: 411-7.
47. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 2002; 161: 1773-81.
48. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-21.
49. Wingler K, Wunsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001; 31: 1456-64.
50. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: Role of NAD(P)H oxidase. Mol Cell Biochem 2004; 264: 85-97.
51. Hordijk PL. Regulation of NADPH oxidases: The role of Rac proteins. Circ Res 2006; 98: 453-62.
52. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-14.
53. Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146: 3900-6.
54. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, et al. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 2005; 336: 163-7.
55. Oberleithner H. Unorthodox sites and modes of aldosterone action. News Physiol Sci 2004; 19: 51-4.
56. Oberleithner H, Riethmuller C, Ludwig T, Hausberg M, Schillers H. Aldosterone remodels human endothelium. Acta Physiol (Oxf) 2006; 187: 305-12.
57. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 2005; 46: 707-13.
58. Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327-34.
59. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-17.
60. Heruti RJ, Sharabi Y, Arbel Y, Shochat T, Swartzon M, Brenner G, et al. The prevalence of erectile dysfunction among hypertensive and prehypertensive men aged 25-40 years. J Sex Med 2007; 4: 596-601.
61. Aversa A, Isidori AM, Gianfrilli D, Greco EA, Graziottin A, Zizzo G, et al. Are subjects with erectile dysfunction aware of their condition? Results from a retrospective study based on an Italian free-call information service. J Endocrinol Invest 2004; 27: 548-56
62. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-81.
63. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and - independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-84.
64. Ucar G, Secil M, Demir O, Demir T, Comlekci A, Uysal S, et al. The combined use of brachial artery flow-mediated dilatation and carotid artery intima-media thickness measurements may be a method to determine vasculogenic erectile dysfunction. Int J Impot Res 2007; 19: 577-83.
65. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: History and impact on cardiovascular disease. Vascul Pharmacol 2006; 45: 268-76.
66. Muguruma H, Kawanishi Y, Sugiyama H, Kagawa J, Tanimoto S, Yamanaka M, et al. Effect of aldosterone on isolated human penile corpus cavernosum tissue. BJU Int 2008; 102: 500-3.
67. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004; 101: 9121-6.
68. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004; 116: 167-79.
69. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-6.
70. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389-99.
71. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-58.
72. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000; 261: 44-51.
73. Chen XQ, Tan I, Ng CH, Hall C, Lim L, Leung T. Characterization of RhoA-binding kinase ROKalpha implication of the pleckstrin homology domain in ROKalpha function using region-specific antibodies. J Biol Chem 2002; 277: 12680-8.
74. Iizuka K, Yoshii A, Samizo K, Tsukagoshi H, Ishizuka T, Dobashi K, et al. A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. Br J Pharmacol 1999; 128: 925-33.
75. Sawada N, Itoh H, Yamashita J, Doi K, Inoue M, Masatsugu K, et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 2001; 280: 798-805.
76. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000; 275: 21722-9.
77. Chang S, Hypolite JA, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003; 15: 53-62.
78. Chitaley K, Wingard CJ, Clinton WR, Branam H, Stopper VS, Lewis RW, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-22.
79. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: Mechanism for age-associated erectile dysfunction. FASEB J 2006; 20: 536-8.
80. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-71.
81. Lumbers ER. Angiotensin and aldosterone. Regul Pept 1999; 80: 91-100
82. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: Novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112: 417-28.
83. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25: 1831-6.
84. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005; 28: 925-36.
85. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-8.
86. Callera GE, Montezano AC, Yogi A, Tostes RC, He Y, Schiffrin EL, et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46: 1032-8.
87. Callera GE, Montezano AC, Yogi A, Tostes RC, Touyz RM. Vascular signaling through cholesterol-rich domains: Implications in hypertension. Curr Opin Nephrol Hypertens 2007; 16: 90-104.
88. Sanz-Rosa D, Oubina MP, Cediel E, De las HN, Aragoncillo P, Balfagon G, et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: Vascular functional and structural consequences. Antioxid Redox Signal 2005; 7: 1294-301.
89. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109: 2857-61.
90. Greenblatt DJ, Koch-Weser J. Gynecomastia and impotence: Complications of spironolactone therapy. JAMA 1973; 223: 82
91. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: Mechanism of action. Endocrinology 1975; 97: 52-8.
92. Brown NJ. Eplerenone: Cardiovascular protection. Circulation 2003; 107: 2512-8.
93. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217: 45-52.
94. Lackey K. Medicinal chemistry-29th National Symposium. SERMs and SARMs. IDrugs 2004; 7: 729-31.
95. Kloner R. Erectile dysfunction and hypertension. Int J Impot Res 2007; 19: 296-302.